Congress expands export bank to compete with China—at taxpayer risk
S. 4702 — China Subsidy Response and Export Competitiveness Act of 2026 · Filed by Ruben Gallego (D-AZ) · 1 cosponsor · Introduced Jun 8, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the Export-Import Bank Act to expand the bank's authority to finance and guarantee exports of U.S. goods and services, particularly in competition with Chinese subsidized exports. It broadens the bank's ability to support domestic manufacturing in critical sectors—adding medical manufacturing to the list of eligible industries—and removes language limiting the bank's programs to only "direct" exports and subsidies, allowing it to counter Chinese trade practices more flexibly.
Why we flagged it
The bill's operative mechanism is to expand the Export-Import Bank's authority to finance and guarantee U.S. exports in competition with Chinese subsidies. It is not a subsidy in the traditional sense but rather an expansion of government credit authority—a form of export promotion that benefits U.S. manufacturers and exporters.
What the text implies
- Removal of 'direct' language may allow Ex-Im Bank to finance supply-chain intermediaries and service providers, not just end-product exporters, broadening the scope of beneficiaries beyond traditional manufacturers.
- Medical manufacturing addition is sector-specific carve-out; unclear whether this reflects genuine national-security need or reflects lobbying by medical-device manufacturers seeking export financing.
The full analysis lists 4 implications of this text.
Who stands to gain
U.S. exporters in semiconductor, aerospace, medical manufacturing sectors; U.S. manufacturers competing against Chinese-subsidized goods; Export-Import Bank (expanded mandate and potential capital deployment)